What a 26% rise in coupling-reagent prices does to a 20 mg vial
Follow the resin, not the catalogue.
Archive — May 2026
Page 2 of 5 of this archive, newest first.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
From the floor in Chengdu: 23 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Independent analysis puts a QYB mazdutide lot at 95.3%, against 92.9% on the certificate
The result is unremarkable. What the report states alongside it is not.
The word “confirmed” is doing an enormous amount of work on this certificate
The Journal’s standing position: a mass that matches is necessary evidence of identity and nowhere near sufficient.
The specification sheet says 500,000. The report says conforms.
Every instrument specification quoted in an advertisement is a best case obtained on a calibration mixture, not on a submitted vial.
What the new the United Arab Emirates guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
TRIUMPH-1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Portugal health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.
PeptideMeter result on a Wuxi dulaglutide lot lands 2.2 points above the supplier’s stated figure
The report states the gradient, the wavelength and the integration threshold, which is more than most.
Tolerability is the ceiling, and the ceiling is personal
An effect is dose-limiting when it prevents adequate intake, prevents normal activity, or produces a risk of its own. Discomfort alone is not the test.
Escalating past the approved maximum, examined honestly
We looked at what the dose-ranging data supports about going higher, and it is thinner and less flattering than the market assumes.
Continued treatment against continued placebo: the comparison that settled it
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
What changed at QST in May, and what the company says prompted it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Nigeria caps exenatide prescribing to 23 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
The relabeller trading as Vantris Bio closes after 24 years
A proper account of an operation that existed, and of what closing it cost.
LAL, kinetic chromogenic, recombinant factor C: three ways to the same figure
The limit for a parenteral product is calculable from the dose and the body weight in two lines. Almost nobody in this trade performs the calculation.
STEP 1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The United Arab Emirates declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Halvard & Pike Apothecary of Portland, Maine enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
A shortage listing ends. 9 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
How a claim degrades between the bench and the listing
Lot-level verification with a public report is a real and achievable thing. It exists in this market, on a minority of listings.
Reading HbA1c in the presence of anaemia
The alternatives with shorter windows, what they measure, and why they are rarely ordered.
PeptideMeter result on a Changsha mazdutide lot lands 4.4 points above the supplier’s stated figure
The report states the gradient, the wavelength and the integration threshold, which is more than most.
What changed at QST in May, and what the company says prompted it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
A supplier suspends shipping to the United Kingdom after 14 consecutive customs detentions
The route did not close because of a rule about peptides.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
When a better instrument changes the answer rather than the confidence
Calibration drift is real, unremarkable, and the reason serious laboratories run internal standards.
What the GIP receptor adds: reading cagrilintide as two drugs in one sequence
Head-to-head data exists for some of these comparisons and not for others. This piece says which.
Xianning export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
The 28-day notice: how a compounding wind-down works in South Korea
The document is four pages. Three of them are about dates.
Inspectors cite Calder Vale Peptides of Skipton over sterility assurance
The observation that closes a facility is rarely the dramatic one.
Aseptic technique for people who were never taught it
A needle blunts on first use. Reuse is uncomfortable, and it is a documented contributor to lipohypertrophy.
What orthogonal actually means, and what it does not
Aggregates dissociate in the mobile phase and are recorded as monomer. Only a size-based separation reports them.
What the new Switzerland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
A supplier suspends shipping to Argentina after 22 consecutive customs detentions
The route did not close because of a rule about peptides.
The relabeller trading as Vantris Bio enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Independent analysis puts a Homopeptide retatrutide lot at 98.3%, against 97.3% on the certificate
The result is unremarkable. What the report states alongside it is not.
What SELECT reported for HbA1c, and from which baseline
A robust, cheap, standardised assay with a specific and well-catalogued set of failure modes, several of which are common in this population.
What the placebo arms of the withdrawal trials actually tell us
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.